UK MHRA inspection at Indoco Goa Plant I clears with no major issues
INDOCO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 11.5 pts more than Nifty Microcap 250 and 11.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
UK MHRA conducted cGMP inspection at Indoco Remedies' Plant I (solid oral dosage facility) in Goa from September 7 to 9, 2026. The inspection concluded with no critical or major observations. This facility contributes about 30 percent of total international business and serves regulated markets including UK, Europe, South Africa, New Zealand, Australia and Canada. The plant is also approved by USFDA, TGA-Australia, EU Malta, WHO-GMP and SAHPRA.
Positive regulatory outcome at key export facility covering 30 percent of international business. Reinforces global quality credentials and export continuity.